Suchergebnisse
Suchergebnisse:
Wir führen Sie durch die spannende Welt der Immuntherapien. Hier finden Sie Informationen zur Grundlagenforschung und zu neuartigen Behandlungsmöglichkeiten.
Our goal is clear: we want to provide better medicines for patients worldwide. Our toolbox includes a broad range of drug classes and platform technologies including mRNA-based therapies, cell therapies, small molecules as well as antibodies and other protein-based therapies.
Welcome to the BioNTech Newsroom. In this section you can find a variety of media materials and useful information to download. Latest News. May 17, 2024. BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024. June 1, 2024.
BioNTech es una empresa líder en biotecnología que desarrolla medicamentos innovadores basados en el ARNm, la terapia celular, las moléculas pequeñas y las proteínas. Descubra cómo BioNTech puede mejorar la salud de los pacientes en todo el mundo.
21. Mai 2024 · Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases.
18. Dez. 2023 · Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
Vor 5 Tagen · You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech's Report on Form 6-K for the period ended March 31, 2024, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof ...
Vor 2 Tagen · You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech's Report on Form 6-K for the period ended March 31, 2024, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any ...
9. Apr. 2020 · The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the United States and Europe across multiple sites. BioNTech and Pfizer intend to initiate the first clinical trials as early as the end of April 2020, assuming regulatory clearance.
BioNTech SE (/ b iː ˈ ɒ n t ɛ k / bee-ON-tek; or / b aɪ ˈ ɒ n t ɛ k / bye-ON-tek short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
